Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression

Takuma Hayashi, Yuto Shimamura, Taro Saegusa, Akiko Horiuchi, Yukihiro Kobayashi, Nobuyoshi Hiraoka, Yae Kanai, Hiroyuki Aburatani, Kenji Sano, Ikuo Konishi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass. Typical presentations with hypercalcemia or eosinophilia have been reported. Radiographic evaluation with combined positron emission tomography/computed tomography may assist in the diagnosis and surveillance of women with uterine LMS. A recently developed risk-assessment index is highly predictive of disease-specific survival. Ovarian preservation does not appear to negatively impact outcome, and the addition of adjuvant therapy after surgical treatment does not seem to improve survival. It is noteworthy that LMP2-deficient mice exhibit spontaneous development of uterine LMS with a disease prevalence of ∼37% by 12 months of age. The LMP2 gene is transcribed from a promoter containing an interferon (IFN-γ-response factor element; thus, the IFN-γ-signal strongly induces LAP2 expression. Furthermore, a recent report demonstrated the loss of ability to induce LMP2 expression, which is an interferon IFN-γ-inducible factor, in human uterine LMS tissues and cell lines. Analysis of human uterine LMS shows somatic mutations in the IFN-γ signalling pathway, thus the loss of LMP2 induction is attributable to a defect in the earliest steps of the IFN-γ signalling pathway. The discovery of an impaired key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

Original languageEnglish
Pages (from-to)297-305
Number of pages9
JournalGene Regulation and Systems Biology
Volume2008
Issue number2
Publication statusPublished - 2008 Jul 22
Externally publishedYes

Fingerprint

leiomyosarcoma
Interferons
Leiomyosarcoma
defect
Cell signaling
Defects
Positron emission tomography
tomography
Risk assessment
disease prevalence
Tomography
interferons
Genes
Cells
Tissue
mutation
risk assessment
positron-emission tomography
hypercalcemia
somatic mutation

Keywords

  • IFN-γ signalling pathway
  • Leiomyosarcoma
  • lmp2
  • Uterus

ASJC Scopus subject areas

  • Genetics
  • Ecology, Evolution, Behavior and Systematics
  • Computer Science Applications
  • Molecular Biology

Cite this

Hayashi, T., Shimamura, Y., Saegusa, T., Horiuchi, A., Kobayashi, Y., Hiraoka, N., ... Konishi, I. (2008). Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression. Gene Regulation and Systems Biology, 2008(2), 297-305.

Molecular mechanisms of uterine leiomyosarcomas : Involvement of defect in LMP2 expression. / Hayashi, Takuma; Shimamura, Yuto; Saegusa, Taro; Horiuchi, Akiko; Kobayashi, Yukihiro; Hiraoka, Nobuyoshi; Kanai, Yae; Aburatani, Hiroyuki; Sano, Kenji; Konishi, Ikuo.

In: Gene Regulation and Systems Biology, Vol. 2008, No. 2, 22.07.2008, p. 297-305.

Research output: Contribution to journalReview article

Hayashi, T, Shimamura, Y, Saegusa, T, Horiuchi, A, Kobayashi, Y, Hiraoka, N, Kanai, Y, Aburatani, H, Sano, K & Konishi, I 2008, 'Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression', Gene Regulation and Systems Biology, vol. 2008, no. 2, pp. 297-305.
Hayashi T, Shimamura Y, Saegusa T, Horiuchi A, Kobayashi Y, Hiraoka N et al. Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression. Gene Regulation and Systems Biology. 2008 Jul 22;2008(2):297-305.
Hayashi, Takuma ; Shimamura, Yuto ; Saegusa, Taro ; Horiuchi, Akiko ; Kobayashi, Yukihiro ; Hiraoka, Nobuyoshi ; Kanai, Yae ; Aburatani, Hiroyuki ; Sano, Kenji ; Konishi, Ikuo. / Molecular mechanisms of uterine leiomyosarcomas : Involvement of defect in LMP2 expression. In: Gene Regulation and Systems Biology. 2008 ; Vol. 2008, No. 2. pp. 297-305.
@article{855dc12068fc48399e816779e372119a,
title = "Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression",
abstract = "Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass. Typical presentations with hypercalcemia or eosinophilia have been reported. Radiographic evaluation with combined positron emission tomography/computed tomography may assist in the diagnosis and surveillance of women with uterine LMS. A recently developed risk-assessment index is highly predictive of disease-specific survival. Ovarian preservation does not appear to negatively impact outcome, and the addition of adjuvant therapy after surgical treatment does not seem to improve survival. It is noteworthy that LMP2-deficient mice exhibit spontaneous development of uterine LMS with a disease prevalence of ∼37{\%} by 12 months of age. The LMP2 gene is transcribed from a promoter containing an interferon (IFN-γ-response factor element; thus, the IFN-γ-signal strongly induces LAP2 expression. Furthermore, a recent report demonstrated the loss of ability to induce LMP2 expression, which is an interferon IFN-γ-inducible factor, in human uterine LMS tissues and cell lines. Analysis of human uterine LMS shows somatic mutations in the IFN-γ signalling pathway, thus the loss of LMP2 induction is attributable to a defect in the earliest steps of the IFN-γ signalling pathway. The discovery of an impaired key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.",
keywords = "IFN-γ signalling pathway, Leiomyosarcoma, lmp2, Uterus",
author = "Takuma Hayashi and Yuto Shimamura and Taro Saegusa and Akiko Horiuchi and Yukihiro Kobayashi and Nobuyoshi Hiraoka and Yae Kanai and Hiroyuki Aburatani and Kenji Sano and Ikuo Konishi",
year = "2008",
month = "7",
day = "22",
language = "English",
volume = "2008",
pages = "297--305",
journal = "Gene Regulation and Systems Biology",
issn = "1177-6250",
publisher = "Libertas Academica Ltd.",
number = "2",

}

TY - JOUR

T1 - Molecular mechanisms of uterine leiomyosarcomas

T2 - Involvement of defect in LMP2 expression

AU - Hayashi, Takuma

AU - Shimamura, Yuto

AU - Saegusa, Taro

AU - Horiuchi, Akiko

AU - Kobayashi, Yukihiro

AU - Hiraoka, Nobuyoshi

AU - Kanai, Yae

AU - Aburatani, Hiroyuki

AU - Sano, Kenji

AU - Konishi, Ikuo

PY - 2008/7/22

Y1 - 2008/7/22

N2 - Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass. Typical presentations with hypercalcemia or eosinophilia have been reported. Radiographic evaluation with combined positron emission tomography/computed tomography may assist in the diagnosis and surveillance of women with uterine LMS. A recently developed risk-assessment index is highly predictive of disease-specific survival. Ovarian preservation does not appear to negatively impact outcome, and the addition of adjuvant therapy after surgical treatment does not seem to improve survival. It is noteworthy that LMP2-deficient mice exhibit spontaneous development of uterine LMS with a disease prevalence of ∼37% by 12 months of age. The LMP2 gene is transcribed from a promoter containing an interferon (IFN-γ-response factor element; thus, the IFN-γ-signal strongly induces LAP2 expression. Furthermore, a recent report demonstrated the loss of ability to induce LMP2 expression, which is an interferon IFN-γ-inducible factor, in human uterine LMS tissues and cell lines. Analysis of human uterine LMS shows somatic mutations in the IFN-γ signalling pathway, thus the loss of LMP2 induction is attributable to a defect in the earliest steps of the IFN-γ signalling pathway. The discovery of an impaired key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

AB - Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass. Typical presentations with hypercalcemia or eosinophilia have been reported. Radiographic evaluation with combined positron emission tomography/computed tomography may assist in the diagnosis and surveillance of women with uterine LMS. A recently developed risk-assessment index is highly predictive of disease-specific survival. Ovarian preservation does not appear to negatively impact outcome, and the addition of adjuvant therapy after surgical treatment does not seem to improve survival. It is noteworthy that LMP2-deficient mice exhibit spontaneous development of uterine LMS with a disease prevalence of ∼37% by 12 months of age. The LMP2 gene is transcribed from a promoter containing an interferon (IFN-γ-response factor element; thus, the IFN-γ-signal strongly induces LAP2 expression. Furthermore, a recent report demonstrated the loss of ability to induce LMP2 expression, which is an interferon IFN-γ-inducible factor, in human uterine LMS tissues and cell lines. Analysis of human uterine LMS shows somatic mutations in the IFN-γ signalling pathway, thus the loss of LMP2 induction is attributable to a defect in the earliest steps of the IFN-γ signalling pathway. The discovery of an impaired key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

KW - IFN-γ signalling pathway

KW - Leiomyosarcoma

KW - lmp2

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=77953387744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953387744&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77953387744

VL - 2008

SP - 297

EP - 305

JO - Gene Regulation and Systems Biology

JF - Gene Regulation and Systems Biology

SN - 1177-6250

IS - 2

ER -